Search Site
Home » Blogs » Recommendation Updates » Pfizer FDA Approval Received
Large Cap / Pharmaceuticals, Biotechnology & Life Sciences
PFE Obtains FDA Approval for Lyrica

Pfizer FDA Approval Received

June 21, 2012
KEYWORDS PFE / Pfizer / Pfizer Inc. / Pfizer, Inc. / Pfizer Inc. (NYSE: PFE) / Pfizer Inc. FDA approval / Pfizer FDA / Pfizer FDA approval
 / Print / Reprints /
| Share More
/ Text Size+
Larger Smaller
[X]

On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.

To view the full article, please subscribe or login.

Profit from The Turnaround Letter's...

  • Market-Beating Investment Results
  • 25+ Years of Turnaround Experience
  • Diverse Stock Picks for Today's Unpredictable Market

TLCorner

Time to Pay the Piper: 7 Strategies to Minimize Tax Pain

“No taxes can be devised which are not more or less inconvenient and unpleasant.” ~ George Washington Read More.

Europe’s Not Out of the Woods Yet, But…

The latest banking crisis in Europe, this time in the tiny island nation of Cyprus, shows that the continent has not yet truly solved its financial problems. It has only applied a series of band-aids that have temporarily averted disaster, but have not yet provided a firmer long-term footing for the Euro-bloc. There could be another crisis of confidence at almost any time, with Italy and Spain being the most likely instigators. Read More.

What did The Turnaround Letter see that others did not?

What did The Turnaround Letter see in these companies that others did not?

Questions & Tips

AskGeorge

Why are you still recommending MGIC?

I don’t normally comment on individual stocks in this particular blog, but the MGIC situation represents a basic investment principle that is worthy of discussion here.

Read More.

How important are Price-to-Earnings (P/E) ratios in evaluating turnaround stocks?

Price-to-Earnings ratios are probably the most widely used tool for comparing the relative values of different stocks.

Read More.

Does the poor performance of the stock market in May indicate that the U.S. is headed for a new recession?

This question comes up frequently when the market takes a dip.

Read More.

Barron's Proclaims:

"For 21 years, George Putnam III has trained his sights on one of the more obscure areas of investing: turnaround situations and bankruptcies. By focusing on out-of-favor companies, his flagship publication, The Turnaround Letter, has achieved enormous success for its subscribers."

 

MOSTPOPULAR

Purchase Recommendation - June 2013

Major Oil Stocks: Low Valuations & High Yields

Data Storage Stocks: Repositories of Value & Opportunity?

Sale Recommendations - June 2013

Updates for June 2013: Purchase Price Raised for Interpublic, Boston Scientific, Ford, Marsh & Fifth Third